The Clinical Actionability Gap in Rare Disease Therapeutics

We have to get a lot faster at discovering drugs. Traditional small molecule kind of bottom up drug discovery, you're talking about generally three years from the selection of a target to having a tool molecule that you can use in an animal. Anything you can do to increase the arsenal will have massive outsized impact and oncology. Are there other disease areas where you think we have that same massive mismatch or massive gap between being target rich and tool poor?